Tvardi Therapeutics (TVRD) Equity Average (2016 - 2025)
Tvardi Therapeutics' Equity Average history spans 13 years, with the latest figure at $24.4 million for Q4 2025.
- On a quarterly basis, Equity Average rose 128.77% to $24.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.4 million, a 128.77% increase, with the full-year FY2025 number at -$35.1 million, up 54.18% from a year prior.
- Equity Average hit $24.4 million in Q4 2025 for Tvardi Therapeutics, down from $30.4 million in the prior quarter.
- Over the last five years, Equity Average for TVRD hit a ceiling of $239.7 million in Q1 2021 and a floor of -$95.9 million in Q1 2025.
- Historically, Equity Average has averaged $83.8 million across 5 years, with a median of $110.0 million in 2023.
- Biggest five-year swings in Equity Average: tumbled 819.28% in 2024 and later skyrocketed 140.11% in 2025.
- Tracing TVRD's Equity Average over 5 years: stood at $217.4 million in 2021, then dropped by 20.96% to $171.8 million in 2022, then tumbled by 93.14% to $11.8 million in 2023, then tumbled by 819.28% to -$84.8 million in 2024, then surged by 128.77% to $24.4 million in 2025.
- Business Quant data shows Equity Average for TVRD at $24.4 million in Q4 2025, $30.4 million in Q3 2025, and -$33.8 million in Q2 2025.